Kaku et al. demonstrate that the efficacy of neutralizing mAbs and convalescent plasma is maintained against SARS-CoV-2 variants B.1.1.7 from the UK and mink cluster 5 but decreases against B.1.351 from South Africa and P.1 from Brazil. Rapid spread of these variants significantly impacts SARS-CoV-2 therapies and vaccine strategies.
Comments are closed.